Clofazimine and dapsone compliance in leprosy

The regularity with which multi bacillary patients, who were being treated with the WHO Study Group regimen in a THELEP-sponsored field trial in South India, ingested their prescribed daily clofazimine and dapsone was studied. The ingestion of clofazimine was monitored using a specially prepared fo rmulation containing minute amounts of isoniazid as an innocuous marker. Overall drug acceptability and compliance was excellent. Approximately 75% of the prescribed daily clofazimine and dapsone doses were being ingested and it was concluded that only 5% of the patients would have benefited if their treatment had been supplemented by acedapsone injections.